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The Leukotriene C4 Transporter MRP1 Regulates
CCL19 (MIP-3b, ELC)–Dependent Mobilization
of Dendritic Cells to Lymph Nodes
dues. LTB4 and LTC4 are secreted from cells through
the action of distinct transmembrane transporters (Dra-
zen et al., 1999). The ATP-binding cassette superfamily
member multidrug resistance-associated protein 1 (MRP1)
transports LTC4 (Leier et al., 1994), and failure to express
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cysLT1 receptor and cysLTs interfere with the known
physiologic effects of cysLTs (Labat et al., 1992). Among
the cysLTs, LTD4 has the highest affinity for the cysLT1Summary
receptor. Messenger RNA for this receptor is most abun-
dant in spleen and peripheral blood leukocytes, and isAdaptive immune responses begin after antigen-bear-
also expressed in small intestine and lung (Lynch et al.,ing dendritic cells (DCs) traffic from peripheral tissues
1999). Cells that have the capacity to produce LTC4to lymph nodes. Here, we show that DC migration from
include mast cells, basophils, eosinophils (Lewis et al.,
skin to lymph nodes utilizes the leukotriene C4 (LTC4) 1990), and dendritic cells (DCs) (Spanbroek et al., 1998,
transporter multidrug resistance-associated protein 1
2000).
(MRP1). DC mobilization from the epidermis and traf-
Antigen-presenting DCs initiate immune responses
ficking into lymphatic vessels was greatly reduced in after they acquire antigens in the periphery and migrate
MRP12/2 mice, but migration was restored by exoge- to draining lymph nodes, where they localize in the T
nous cysteinyl leukotrienes LTC4 or LTD4. In vitro, these cell–rich paracortex. DCs can be mobilized from the
cysteinyl leukotrienes promoted optimal chemotaxis periphery by inflammatory stimuli such as IL-1, TNFa,
to the chemokine CCL19, but not to other related che- or bacterial LPS. These mediators cause DCs to mature
mokines. Antagonism of CCL19 in vivo prevented DC and to express the chemokine receptor CCR7 (Cyster,
migration out of the epidermis. Thus, MRP-1 regulates 1999). CCR7 coordinates the accumulation and organi-
DC migration to lymph nodes, apparently by trans- zation of DCs and T cells in lymph nodes (Fo¨rster et al.,
porting LTC4, which in turn promotes chemotaxis to 1999; Randolph et al., 1999b; Sallusto et al., 1999). Both
CCL19 and mobilization of DCs from the epidermis. characterized chemotactic ligands for CCR7, CCL19
(using new nomenclature proposed by Zlotnik and
Yoshie [2000]; also called MIP-3b or ELC), and CCL21Introduction
(6-C-kine or SLC), are expressed in the lymph node
paracortex (Gunn et al., 1998; Ngo et al., 1998). CCL21The cysteinyl leukotrienes (cysLTs) leukotriene C4 (LTC4),
is also expressed by afferent lymphatic endotheliumLTD4, and LTE4 are mediators of immediate hypersensi-
(Gunn et al., 1998) and appears to act as a key mediatortivity reactions, and they are most well characterized
of DC and T cell trafficking to the lymph node (Gunn etas potent agonists of bronchoconstriction and vascular
al., 1999; Saeki et al., 1999). Studies to date have not yetpermeability (Samuelsson et al., 1987; Drazen et al.,
addressed whether CCL19 participates in DC migration1999). Consistent with these biologic activities, abun-
from the periphery to lymph nodes.dant production of cysLTs correlates with bronchial
In our effort to define the molecular events that medi-asthma attacks. The synthesis of cysLTs is regulated
ate DC migration into afferent lymphatic vessels, weby the action of 5-lipoxygenase (5-LO), which catalyzes
previously identified a role for the lipid transporter multi-the conversion of arachidonic acid to leukotriene A4.
drug resistance protein 1 (MDR-1). Blocking the trans-This unstable epoxide is converted by LTA4 hydrolase
port activity of MDR-1 prevents DCs from migrating outto LTB4, a potent chemoattractant for inflammatory cells,
of the epidermis of human skin explants (Randolph etor to nonchemotactic LTC4 by LTC4 synthase-mediated
al., 1998). Now we report that the additional multidrugconjugation of LTA4 with cysteine and glutathione resi-
resistance family member and LTC4 transporter multi-
drug resistance associated protein 1 (MRP1) is also ex-
§ To whom correspondence should be addressed (e-mail: gwendalyn. pressed by DCs and is necessary for their entry into
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neutralizing Ab to CCL19 strongly reduced DC accumu-
lation in LNs in a model of contact sensitization.
Results
Expression and Functional Activity
of MRP1 in DCs
The expression of multidrug resistance transporters was
first assayed in DCs that migrated from mouse ear ex-
plants. Flow cytometric evaluation of permeabilized
mouse DCs using an mAb that would identify both of
the two murine homologs of human MDR-1 and an mAb
against MRP1 revealed the expression of MRP1 in
mouse DCs, but did not clearly show expression of
MDR-1 gene products (Figure 1A).
The functional activity of multidrug resistance trans-
porters was assessed by loading DCs with a fluorescent
transport substrate and then measuring the units of fluo-
rescence retained in the cells over a period of time
(Chaudhary and Roninson, 1991). Loss of fluorescence
at 378C indicates transport of the dye from the intracellu-
lar to the extracellular compartment. The synthetic sub-
strate Fluo-3 is transported efficiently by MRP1 (Lohoff
et al., 1998). Efflux of Fluo-3 was evident in MRP11/1
DCs that emigrated from lymphatic vessels of mouse
skin explants (Figure 1B), and this efflux was blocked by
the MRP antagonist MK571 (not shown). Double knockout
mice lacking expression of MDR1a and MDR1b also ef-
fluxed Fluo-3 (Figure 1B). In contrast, mice that lacked
MRP1 did not transport Fluo-3 (Figure 1B). Efflux activity
profiles were similar whether we used DCs that emi-
grated from skin explants (Figure 1) or DCs derived from
bone marrow progenitors that were generated by 7 days
of culture in GM-CSF (not shown). These data demonstrate
that mouse DCs express functional MRP1 and that lack of
its expression alters the transport of an MRP1 substrate, Figure 1. Expression of Multidrug Resistance Transporters in
suggesting that functionally redundant transporters of Mouse and Human DCs
MRP1 are not expressed in MRP12/2 DCs. (A) Ear explants from wild-type (FVB/N) mice were cultured for 3
We had previously detected the expression of MDR-1 days. Emigrated DCs were permeabilized and stained with anti-
MDR-1, anti-MRP1, or with species- and isotype-matched controlin human skin DCs (Randolph et al., 1998), but had not
mAbs. 2A1 mAb recognizes an intracellular DC marker and wasexamined the expression of MRP1. We conducted im-
used as a positive control for adequate permeabilization.munoblot analysis of microsomal membranes prepared
(B) DCs that emigrated from mouse ear explants were loaded withfrom human DCs that had emigrated from skin explants
the fluorescent transporter substrate Fluo-3 and washed. The “load-
and compared the expression pattern of these trans- ing control” was kept at 48C (filled profiles) while other samples were
porters to that observed in mouse DCs. Human DCs incubated at 378C for 60 min. (open profiles). Cells were washed,
expressed both MRP1 and MDR-1, whereas mouse DCs and fluorescence was measured by flow cytometry. Data from the
relevant wild-type counterparts are plotted just above that of thereacted only very weakly with anti-MDR-1 mAb (Figure
knock-out mice.1C). Thus, MRP1 is highly expressed in both mouse and
(C) Western blots using the anti-MRP1 and anti-MDR-1 mAbs, whichhuman DCs.
react with both the human and mouse species of the respective
transporters that they recognize, were conducted on microsomes
Role of MRP1 in DC Migration from Human prepared from mouse bone marrow–derived DCs (Mu DCs) or DCs
Skin Explants that emigrated from human skin (Hu DCs) after 2 days. Microsomal
We next investigated the role of MRP1 in the mobilization proteins were separated on a 4%–12% gradient gel (5 mg total
protein in each lane) and immunoblotted.of both human and mouse DCs. To test the role of MRP1
in human DC migration, we added the LTD4 analog and
MRP1 antagonist MK571 to the medium of human skin
findings suggest that MRP1 is required for migration ofexplants. The drug very effectively blocks MRP1-medi-
human skin DCs.ated transport of LTC4 (Leier et al., 1994) but does not
antagonize MDR-1 (Nuessler et al., 1997). When added
Role of MRP1 in Migration of Epidermal Dendriticto the medium of cultured human skin explants, MK571
Cells to Lymph Nodes In Vivoinhibited emigration of DCs and T cells in a concentra-
Application of FITC to the skin of mice induces contacttion-dependent manner, blocking by 67% 6 7% at the
sensitivity resulting from the migration of FITC1 epider-highest concentration tested of 25 mM (Figure 2). These
mal DCs to the draining lymph node (Kripke et al., 1990;concentrations of MK571 did not adversely affect the
viability of cultured DCs (data not shown). Thus, the Sato et al., 1998). Before employing this model, we de-
Role of MRP1 in Dendritic Cell Migration
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Figure 2. Effects of the MRP1 Antagonist MK571 on Migration of
Human DCs and T Cells from Skin Explants
Explants of human skin, trimmed to 4 cm2, were floated in culture
medium containing MK571 at the indicated concentrations. The
number of DCs and T cells that emigrated into the cultured medium
after 2 days of incubation were quantified and expressed relative
to the number of cells that migrated from the explants in medium
lacking MK571. MK571 is soluble in aqueous medium, obviating the
need for a solvent carrier. The experiment was repeated 4 times,
with 3 replicates of skin used for a given concentration of MK571
in each experiment.
termined the density of DCs in the epidermis and found
that it was similar among wild-type, MRP2/2, and
MDR1a/1b2/2mice (800–900 epidermal DCs / mm2). The
accumulation of CD11c1FITC1 DCs in lymph nodes was
then determined in these mouse strains 18 hr after appli-
cation of FITC, when the migration of FITC1 wild-type
DCs to the lymph node becomes maximal (data not
shown). MDR1a/1b2/2mice showed only a slight average
reduction (10%) in the accumulation of FITC1 DCs in
draining lymph nodes, which was not statistically signifi-
Figure 3. Role of MRP1 in Mouse DC Trafficking to Lymph Nodescant. However, in the lymph nodes of MRP12/2 mice,
FITC was applied to the shaved dorsal skin of mice in areas thatthe number of CD11c1FITC1 DCs that accumulated was
drain to the axillary, brachial, and inguinal lymph nodes. After 1876% lower than in matched controls (Figure 3). These hr, the accumulation of FITC1cells (x axis) in these lymph nodes
results demonstrate a role for MRP1 in the migration of was quantified. DCs were identified using PE-conjugated anti-
DCs in vivo. CD11c mAb (y axis). Data from the relevant wild-type counterparts
are plotted just above that of the knockout (k/o) mice. Quadrants
are positioned such that the lower left quadrant represents theNormal Cellular Distribution in Lymphoid Organs
boundaries observed when cells were stained with negative control
of MRP1-Deficient Mice mAbs (not shown). All plots show 50,000 total lymph node cells.
Splenomegaly was apparent in MRP1-deficient mice, Data are derived from 5 independent experiments. To compare re-
but the lymph nodes contained a similar number of cells sults from different experiments, data were normalized by dividing
the number of FITC1CD11c1 DCs from each individual by the aver-as their normal counterparts. In both spleen (not shown)
age number of FITC1CD11c1 DCs in the normal MRP11/1 controlsand lymph nodes (Figure 4), the anatomic distribution
in the same experiment. Typically, there were about 1 3 105 FITC1of B cells, T cells, and DCs was normal. This was true
DCs in the control samples. The relative numbers of FITC1CD11c1
in the steady state and after application of FITC (Figure DCs were graphed in a scatter plot to indicate the results obtained
4). However, 18 hr after FITC painting, only lymph nodes from each individual mouse tested. The differences between
from MRP11/1 mice contained FITC1 DCs, and these MRP11/1 and MRP12/2 mice are statistically significant, p less than
or equal to 1 3 1027.cells were deep to the B2201 B cell follicles in the CD81
T cell–rich regions (Figure 4A), colocalizing with the DC
marker 2A1 (Inaba et al., 1992a) (Figure 4B).
(Gretz et al., 1997). These findings suggest that DCsIn both MRP11/1 and MRP12/2 lymph nodes, some
carry FITC to lymph nodes in mice that express MRP1,FITC was observed within and around germinal centers
but in the absence of this transporter, only soluble FITCand in the subcapsular space, but did not colocalize
accumulates in conduits within the lymph node.with cellular markers that we examined, including B220
(Figure 4A), CD4, CD8 (Figure 4A), CD11b, CD11c, 2A1
(Figure 4B), and the macrophage marker SER-4 (Crocker Retention of DCs in the Epidermis and Dermis
of MRP1-Deficient Miceand Gordon, 1986). Rather, it was seen in long, channel-
like structures (Figure 4A), resembling descriptions of Because FITC1 DCs did not appear in the lymph nodes
of MRP1-deficient mice, we wondered if they werethe distribution of soluble tracers within lymph nodes
Cell
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Figure 4. Immunohistologic Analysis of Lymph
Nodes in Normal and MRP12/2 Mice 18 hr
after Application of FITC
Immunostaining of frozen sections of lymph
nodes was conducted using PE-conjugated
(red) anti-B220 (A), PE-conjugated anti-CD8
(A), or anti-DC mAb 2A1 (B) detected with
Cy3-conjugated (red) anti-rat IgG. Staining
with isotype-matched control mAbs was neg-
ative. FITC appears green. (A) low power
magnification; (B) high power magnification.
For orientation, arrows in (A) demarcate the
capsule/edge of the lymph node section.
trapped in the periphery. We observed numerous Impaired Migration of MRP12/2 DCs to Lymph
Nodes is Corrected by Exogenous CysteinylFITC1MHC II1 DCs remaining in the epidermis of
MRP12/2 mice, even 18 hr after application of FITC, Leukotrienes LTC4 or LTD4
Because LTC4 is a high affinity substrate for MRP1, wewhen many DCs in the epidermis of control mice had
already migrated to the lymph node (Figures 5A and investigated whether this cysLT may mediate DC traf-
ficking to lymph nodes. Indeed, we observed a markedly5B). Dermal cords, corresponding to lymphatic vessels
(Lukas et al., 1996), were filled with MHC II1 cells in diminished accumulation of DCs in the lymph nodes of
5-LO-deficient mice, which due to the lack of this en-MRP11/1 sections (Figure 5A), but accumulation of MHC
II1 cells in such cords was uncommon in MRP12/2 skin zyme, would be incapable of synthesizing LTC4. The re-
sults from 5-LO2/2 mice, then, are consistent with a role(Figure 5B). At 18 hr following application of FITC, few
of the migrating cells in control lymphatics were FITC1 for 5-LO products such as LTC4 in Langerhans cells
migration. However, interpretation of this finding is con-(Figure 5A), likely because FITC1 DCs had already ar-
rived in the draining lymph nodes. founded by an apparent reduction in Langerhans cell
density in the epidermis of 5-LO2/2 mice (data notDermal FITC1 cells were rare in MRP1/1 mice 18 hr
after FITC application (Figure 5C), but focal collections shown). Thus, we turned to additional approaches to
analyze the role of LTC4 in DC mobilization from theof FITC1 cells were apparent in the dermis of MRP1-
deficient mice (Figure 5D). VE-cadherin (cadherin 5) is skin.
Intracutaneous injection of exogenous LTC4 6 hr afterexpressed on all endothelium, including lymphatic en-
dothelium (Wigle and Oliver, 1999). Interestingly, many application of FITC substantially increased the number
of FITC1 DCs that migrated to lymph nodes in MRP12/2of the FITC1 cells in the dermis were closely associated
with VE-cadherin-staining vessels (Figure 5E). These mice compared to normal controls (Figures 6A and 6B).
The area of the skin covered by FITC is large and ex-dermal FITC1 cells colocalized with DC markers CD11c
(Figure 5F) and DEC-205 (not shown). Quantitative analy- ceeds the area that would be directly exposed to the
cysLTs, which were injected into the skin in a smallsis revealed 7 times more FITC1 cells in the dermis of
MRP12/2 mice than in MRP11/1 mice (Figure 5G). volume to minimize hydrostatic pressure on the local
Role of MRP1 in Dendritic Cell Migration
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Figure 5. Immunolocalization of DCs in the
Skin after FITC Application
Cross-sections of ear skin from MRP11/1 and
MRP12/2 mice were prepared 18 hr after ap-
plication of FITC to the epidermis (green or
yellow). Cell surface markers were analyzed
using red fluorescent reagents: anti-MHC II
(A and B), anti-VE-cadherin (cadherin 5; Cad
5) (C–E), or anti-CD11c (F). (A–D) low power;
(E–F) high power. (G) The number of FITC1
cells in the dermis, and their relationship to
VE-cadherin1 vessels, was counted in multi-
ple sections (from three mice per genotype)
and is reported as a function of the length of
sectioned skin analyzed.
lymphatics. Thus, a full reversal of the inhibitory pheno- to the effect of LTC4, injection of equimolar concentra-
tions of LTA4 caused no increase in mobilization of DCstype was not expected. The increased level of FITC
(x axis, Figure 6A) found in individual MRP12/2 DCs to lymph nodes in MRP12/2 mice (Figure 6C).
Because some apparently soluble FITC accumulatescompared to DCs from MRP11/1 mice is most likely
because FITC can be transported out of the cells by in lymph nodes (Figure 4), we wanted to determine
whether exogenous LTC4 was really acting at the level ofMRP1 (data not shown), so that cells lacking the trans-
porter would tend to accumulate more FITC. In contrast enhancing DC migration from the periphery, as opposed
Cell
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Figure 6. Effects of Exogenous cysLTs on
DC Mobilization to Lymph Nodes in 2 Models
(A–C) FITC was applied to the skin of
MRP11/1 or MRP12/2 mice. Six hr later, intra-
cutaneous injections of PBS (open bars, [B])
or 300 ng LTC4 (filled bars, [B]) or LTA4 (6
injections per mouse, 3 each side) were made
in areas of skin that had been treated with
FITC. Lymph nodes were analyzed at 18 hr
as described in Figure 3. Each representative
plot shows 50,000 total lymph node cells.
Data shown in B were normalized (see Figure
3) in order to combine values from the two
experiments conducted (n 5 6 for each con-
dition tested).
(D) Fluorescent 1 mm diameter microspheres
were injected intracutaneously into the rear
footpads of MRP12/2 mice. Two days later,
the footpads received 25 ml PBS, 100 ng of
LTC4 or LTD4. Mice were sacrificed 18 hr later
(day 3). Sections of popliteal lymph nodes
were prepared and examined for the extent of
accumulation of microsphere-bearing cells.
to the possibility that it was promoting the acquisition epidermis, through the dermis, and across the intercellu-
lar junctions of lymphatic vessels (Figure 5). This patternof soluble FITC by DCs already present in the lymph
node. Therefore, we used a different model of DC mobili- of inhibition would be anticipated, for example, under
conditions in which the chemoattraction of cells to lym-zation in which recruited monocytes acquire subcutane-
ously injected microspheres within 18 hr after injection phatic vessels was impaired or suboptimal. Thus, we
studied the chemotactic responses of MRP11/1 andof the microspheres into the skin. A substantial fraction
of these cells then migrate to lymph nodes while simulta- MRP12/2 bone marrow–derived DCs. A somewhat di-
minished chemotactic response to human CCL21 wasneously differentiating into DCs (Randolph et al., 1999a).
Peak accumulation in lymph nodes of these cells occurs observed in MRP12/2 DCs, in which there was an z35%
mean reduction compared to MRP1/1 DCs (Figure 7A).on day 3. In contrast to soluble FITC, free particles do not
readily travel into lymphatics (Randolph et al., 1999a). By More strikingly, MRP1-deficient DCs chemotaxed very
poorly in response to CCL19, with 90% fewer migratingflow cytometry, we observed a decreased accumulation
of microsphere-bearing DCs in the lymph nodes of cells than seen using MRP1/1 DCs (Figure 7A). In con-
trast, the chemotactic response to human CXCL12MRP12/2 mice compared to MRP11/1 controls (data
not shown). To determine whether the accumulation of (SDF-1a) was similar between MRP2/2 and MRP1/1 DCs
(Figure 7B). CCR7, the receptor for CCL19 and CCL21these DCs was promoted by exogenous cysLTs, we
injected microspheres into the subcutaneous tissue of which is expressed on mature DCs, was expressed by
both MRP11/1 and MRP12/2 DCs, as assessed by RT-mouse footpads. Two days later, we injected LTC4, LTD4,
or the vehicle PBS into the footpads. In contrast to PBS PCR (not shown). Interestingly, a 30 min pretreatment
of MRP12/2 DCs with LTD4 induced strong chemotaxisalone (Figure 6D), LTC4 (not shown) or LTD4 (Figure 6D)
induced a massive mobilization of latex-bearing phago- to CCL19 (Figures 7A and 7B), reminiscent of the migra-
tion-promoting effects of cysLTs in vivo. In contrast, thecytes to the lymph node within the ensuing 18 hr. Many
of the cells were found in the T cell area, whereas others cysLTs had no effect on chemotaxis to CCL21 (Figure
7A) or CXCL12 (Figure 7B) or on spontaneous migrationwere located in the subcapsular region. Thus, exoge-
nous cysLTs, either LTC4 or LTD4, reverse the impaired in the absence of added chemoattractant (not shown).
Preincubation with the cysLT1 receptor and MRP1 an-migration of MRP12/2 DCs and their precursors from the
periphery to lymph nodes. tagonist MK571 markedly attenuated chemotactic re-
sponses of MRP11/1 DCs (Figure 7B). Inhibition of MRP1
transport and LTD4 signaling by the addition of MK571Optimal Chemotactic Responses to CCL19 but
Not CCL21 or CXCL12 Requires Signals from was particularly intriguing because it affected chemo-
tactic responses so acutely (30 min to 1 hr preincuba-Extracellular Cysteinyl Leukotrienes
The data indicate that MRP12/2 DCs acquire FITC in tion). This period of time is unlikely sufficient to allow
substantial phenotypic changes stemming from alteredthe skin but are impeded in their migration out of the
Role of MRP1 in Dendritic Cell Migration
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Figure 7. Chemotactic Responses of
MRP11/1 and MRP12/2 DCs to Chemokines
(A and B) DCs from control (MRP11/1) or
MRP1-deficient mice (MRP12/2) were pre-
pared from bone marrow cells cultured for 7
days in the presence of GM-CSF. The chemo-
tactic responses to CXCL12 (10 nM), CCL19
(10 nM in [A], 50nM in [B]), CCL21 (1 mg/ml)
or in the presence of medium lacking chemo-
attractant was assessed using a blindwell
chamber assay. The number of cells that mi-
grated to the bottom surface of filters in 2
hr is plotted. The few migrated cells in the
absence of chemoattractant from sample to
sample (less than 10% of value attributed to
the presence of the chemoattractant) has
been subtracted to evaluate only the migra-
tion that can be attributed to the chemoat-
tractants. These experiments were con-
ducted 4 times with similar results, and each
condition in a given experiment was tested
using triplicates. Before addition to the upper
wells of chemotaxis chambers, cells were
preincubated for 30 min with 100 nM LTD4
(solid bars), 25 mM MK571 (stippled bars), or
control medium (open bars). The cells were
washed to remove these reagents before initi-
ation of chemotaxis assays.
(C) MRP11/1 DCs from human (shown) or
mouse skin explants (not shown) were stud-
ied after pretreatment with MK571 (filled sym-
bols) or control medium (open symbols). Two
experiments were conducted with DCs from
each species, with similar results in all 4 ex-
periments. Standard errors were less than
10% of the mean. Data shown are from an
experiment using human DCs.
transcriptional activity, whereas our use of MRP2/2 DCs pAb (Figure 8A), compared with control normal goat IgG.
Immunohistologic examination of skin sections fromis limited by the possibility that long-term deficiency of
MRP1 could lead to a distinct pathway of differentiation mice receiving these antibodies revealed that treatment
with anti-CCL19 pAb caused a profound retention ofor maturation as compared with MRP1/1 DCs. Thus, we
followed up these observations using the MRP2/2 DCs Langerhans cells in FITC-sensitized epidermis (Figure
8B). Compared with the density of epidermal DCs inwith more extensive chemotactic studies using MRP1/1
DCs. Treatment of MRP11/1 DCs for 1 hr with MK571 the steady state (no FITC applied), there was a mean
reduction of 238 6 98 DCs per mm2 of epidermis in micedepressed chemotactic responsiveness to CCL19 by an
order of magnitude (Figure 7C). This observation was true treated with control IgG. This value corresponds with a
30%–40% loss of DCs from the epidermis. In micewhether we used human (Figure 7C) or mouse skin DCs
(not shown). In striking contrast, responses to CCL21 treated with anti-CCL19, only 7 6 77 DCs per mm2 mi-
grated out of the epidermis (Figure 8B). In contrast,were either not changed or were enhanced by treatment
with MK571 (Figure 7C). Chemotaxis to CXCL12 also accumulations of FITC cells were not observed in the
dermis or in lymph node of anti-CCL19 treated micewas not altered by treatment with MK571 (Figure 7B).
These results indicate that optimal chemotaxis to CCL19 (data not shown).
requires extracellular triggering from cysLTs, but that
chemotaxis to CXCL12 and CCL21 does not. Discussion
A population of DCs continuously traffics through pe-Role of CCL19 in Mobilization of DCs
to Lymph Nodes ripheral tissues and migrates to lymph nodes via afferent
lymphatic vessels. When tissues are perturbed with in-If the role of cysLTs in triggering chemotaxis of DCs to
CCL19 in vitro is relevant to our findings that MRP1 and flammatory or immune stimuli, additional populations of
DCs, including recruited inflammatory cell precursorscysLTs mediate DC trafficking to lymph nodes in vivo,
one would predict that CCL19 is necessary for DC migra- and interstitial DCs, can be mobilized to lymph nodes
(Cyster, 1999). Here, we show that this induced mobiliza-tion to lymph nodes after epicutaneous application of
FITC. Thus, we tested the role of CCL19 in this model tion of peripheral DCs to lymph nodes, either after epicu-
taneous application of FITC (Kripke et al., 1990) or theusing specific neutralizing polyclonal Ab (pAb). A signifi-
cant block in accumulation of DCs in the lymph nodes injection of phagocytic particles (Randolph et al., 1999a),
is greatly attenuated in the absence of functional MRP1.(69% mean inhibition) was achieved with anti-CCL19
Cell
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spleen and in blood leukocytes (Lynch et al., 1999) is
consistent with biologic functions that extend beyond
asthma. As 5-LO, the initial enzyme in the cascade that
controls synthesis of cysLTs, is expressed in skin DCs
(Spanbroek et al., 1998), it is possible that DCs synthe-
size and secrete LTC4 to signal chemotaxis and migra-
tion in an autocrine manner. However, it is unlikely that
DCs depend completely on DC-generated cysLTs, since
other cells such as mast cells can also produce LTC4.
We were led to examine the role of cysLTs in DC
migration while following up on the mechanism by which
multidrug resistance transporters mediated mobilization
of DCs. Upon recognizing that MRP1, the known trans-
porter for LTC4, was necessary for optimal FITC-induced
DC migration to lymph nodes, we turned to the use of
5-LO-deficient mice to test further the role of LTC4 in
DC migration. Whereas DC migration to lymph nodes in
such mice was reduced, as in MRP1-deficient mice, the
nature of the migratory defect in 5-LO-deficient mice
was confounded by a parallel reduction in the number of
epidermal Langerhans cells. This observation suggests
that a 5-LO metabolite may be necessary not only for
DC migration but also for epidermal DC development.
A similar reduction of Langerhans cell density was not
found in MRP12/2 mice. Thus, the absence of an intra-
cellular 5-LO metabolite may account for the reduced
Figure 8. Effects of Neutralizing pAbs to CCL19 on DC Mobilization numbers of DCs in 5-LO-deficient mice. In contrast to
to Lymph Nodes after Epicutaneous Application of FITC 5-LO2/2 mice, intracellular leukotrienes are present in
Purified, normal goat IgG or specific neutralizing goat anti-mouse MRP1-deficient mice (Wijnholds et al., 1997), since the
pAb to CCL19 was injected i.p. (50 mg pAb per mouse) into C57BL/6 defect in these animals is at the level of secretion rather
mice one day before epicutaneous application of FITC.
than in their biosynthesis.(A) Lymph nodes were analyzed 18 hr later as described in Figure
3. The absolute number of FITC1CD11c1 DCs from the pooled lymph
nodes of individual mice is plotted in a scatter diagram. Each mouse Role of Multidrug Resistance Transporters
is delineated by a single data point (squares). Data are combined in DC Migration
from 2 experiments. Four mice were individually evaluated in each While further exploring earlier findings that MDR-1 medi-
experiment (n 5 8 per condition). Results obtained from the use of
ated DC migration in human skin (Randolph et al., 1998),anti-CCL19 pAb differ significantly from mice that received goat
we discovered that murine and human DCs expressIgG, p less than or equal to 0.005.
high levels of another multidrug resistance transporter,(B) Epidermal sheets from thus treated animals were immunostained
with a cocktail of anti-I-Ab mAb and anti-CD11c mAb to identify MRP1. MRP1 is not the closest murine homolog to hu-
epidermal DCs. The number of DCs that migrated from ear epidermis man MDR-1 (Leveille-Webster and Arias, 1995), but it
in mice that were injected with goat IgG control or anti-CCL19 pAb shares in common with MDR-1 a broad substrate speci-
and then treated with FITC was compared with the baseline DC
ficity for a diverse range of lipophilic substrates. How-density obtained from ear skin to which no FITC was applied (n 5
ever, the two enzymes can be distinguished by virtue8 ears evaluated per condition).
of the fact that MRP1 transports substrates that are
conjugated to glutathione or cotransports glutathione
with nonconjugated substrates (Rappa et al., 1997; LoeExogenous administration of the MRP1 substrate LTC4
or its rapidly produced extracellular metabolite LTD4 et al., 1998; Ishikawa, 1992). In some cases, then, MRP1
and MDR-1 may transport similar substrates, but theyreverses this block in DC migration. A key role of the
cysLTs in these events appears to be the triggering of may also have unique and nonoverlapping substrates.
For example, MDR-1 readily transports the chemothera-CCL19-dependent mobilization of DCs to lymph nodes.
peutic agents etoposide and vincristine, but these drugs
are not transported as such by MRP1. When glutathioneRole of CysLTs in Mobilization of DCs
CysLTs have long been recognized as key mediators of is available, however, MRP1 transports etoposide and
vincristine along with glutathione (Rappa et al., 1997;the symptoms of bronchial asthma. A few additional
studies have investigated potential connections be- Loe et al., 1998). As a conjugate of glutathione, LTC4 is
a chemically ideal natural substrate for MRP1, but thistween cysLTs and the pathogenesis of other diseases
such as psoriasis (Lewis et al., 1990). Our data uncover a cysLT is not transported by MDR-1 (Ishikawa et al.,
1990).more global role of cysLTs in inflammation and immunity
than previously appreciated, and indicate their function Overall, our evidence suggests that, rather than being
redundant, the two transporters each have independent,is likely not limited to pathology. Instead, our findings
show that cysLTs are key mediators of DC chemotaxis and key, roles in the trafficking of DCs. Antagonism of
MDR-1 activity in human skin, with specific anti-MDR-1and lymphatic migration.
The abundant expression of cysLT1 receptors in mAbs that do not react with MRP1, potently inhibits
Role of MRP1 in Dendritic Cell Migration
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migration (Randolph et al., 1998). Likewise, the MRP1 DCs express the enzymatic machinery necessary to pro-
duce LTC4 (Spanbroek et al., 1998) and upregulate CCR7antagonist MK571 inhibits human DC migration as
before leaving the epidermis (Saeki et al., 1999), theshown in the present study, although it does not effec-
present data support a model in which cysLT-inducedtively block MDR-1 activity (Nuessler et al., 1997). If the
migration to CCL19 contributes significantly to mobiliza-two transporters had redundant physiological functions,
tion of DCs from the epidermis. Antagonism of CCL19then simultaneous antagonism of both transporters
nearly completely prevented DCs from exiting the epi-would likely be required to impede DC migration. Physio-
dermis. DCs were also predominantly retained within thelogical substrates for MDR-1 have not been clearly de-
epidermis of MRP12/2 mice, but MRP1-deficient micefined, although they are likely to include signaling phos-
additionally showed evidence of DCs that becamepholipids (van Helvoort et al., 1996). Thus, the precise
trapped in focal regions of the dermis. It is reasonablerole of MDR-1 in DC migration remains uncertain.
that the potently neutralizing anti-CCL19 pAb suffi-Other connections between the multidrug resistance
ciently blocked chemotaxis to CCL19 to cause moretransporters and immune regulation of T cells have been
complete retention of DCs at their point of origin inreported, although none reveals a clear mechanism for
the epidermis than observed in the absence of MRP1,their activities. MRP1 is constitutively expressed by Th2
because blocking MRP1 leads to greatly reduced, butcells and is induced on Th1 cells after antigenic stim-
not completely abolished, chemotaxis to CCL19. Thus,ulation (Lohoff et al., 1998). Blocking either transporter
a partially effective response to CCL19 would likely oc-affects cytokine secretion, albeit in different ways.
cur in the absence of MRP1, such that some DCs mightAntagonism of MDR-1 in vitro inhibits T cell secretion
be able to leave the epidermis but then inefficientlyof IL-2, IL-4, and IFN-g, but does not affect the levels
chemotax into lymphatic vessels. Finally, as we alsoof IL-6 (Drach et al., 1996). On the other hand, interfering
found a somewhat reduced chemotaxis of MRP12/2 DCswith MRP1 transport enhances IL-6 secretion (Vellenga
to CCL21 in vitro, a response that was not restored byet al., 1999).
exogenous cysLTs, a suboptimal response to CCL21 of
MRP12/2 DCs may also contribute to the overall migra-Novel Insights into the Roles of CCR7 Ligands
tory defect observed in vivo.in DC Chemotaxis and Migration
It is not yet clear whether multiple chemokines, suchIn the absence of secreted cysLTs, many FITC1 skin
as both CCL19 and CCL21, must be functional for migra-DCs were found adjacent to VE-cadherin1 vessels, con-
tion of DCs to lymph nodes in response to a given stimu-sistent with the possibility that they had migrated to
lus. Neither is it known whether CCL19 is necessary forlymphatic vessels but failed to transmigrate the endo-
migration to lymph nodes in conditions other than wethelium and enter the lymphatic lumen. This observation
have examined here, such as during the steady state.caused us to consider the hypothesis that just as LTC4 Since accumulation of DCs in lymph nodes of MRP12/2mediates vasopermeability by promoting vascular endo-
mice is essentially normal in the steady state, it is possi-thelial retraction at the intercellular borders (Joris et al.,
ble that CCL19 primarily mediates trafficking to lym-1987), a similar action of LTC4 might be necessary to phatic vessels under conditions in which massive mobi-
open lymphatic channels to permit entry of DCs.
lization of DCs from the periphery are induced and that
Whereas we cannot entirely eliminate this possibility,
other chemokines, perhaps CCL21, may mediate steady
further evidence that MRP2/2 DCs were also inhibited
state accumulation of lymph node DCs. Alternatively,
from exiting the epidermis is inconsistent with this hy- because suboptimal chemotactic responses to CCL19
pothesis. Moreover, we included LTA4 in similar assays, can occur in the absence of cysLTs, CCL19-mediated
but this upstream metabolite did not enhance DC migra- trafficking to lymph nodes is more likely delayed rather
tion to lymph nodes, despite that arachidonate and me- than completely blocked in MRP12/2 and 5-LO2/2 mice.
tabolites upstream of formation of the cys-LTs can pro- A slower accumulation of DCs in the lymph node would
mote lymphatic vessel contractility (Johnston et al., be expected to give rise to lymph nodes that appear
1983). normal in the steady state. Finally, it is also possible
The entire body of data that implies impaired DC mi- that small amounts of LTC4 leak from compromised
gration out of the epidermis, through the dermis, and cells in MRP12/2 mice (Wijnholds et al., 1997), and this
across the intercellular junctions of endothelium sug- action might be sufficient to maintain cysLT-dependent
gested that chemotactic responses might be affected. trafficking in the steady state. The development and
Thus, we analyzed the chemotaxis of DCs to several characterization of a CCL192/2 mouse and reagents to
chemokines, including the CCR7 ligands CCL19 and investigate the cell surface expression and subcellular
CCL21. Expression of CCR7 is induced in Langerhans trafficking of murine CCR7 will be valuable tools to ana-
cells as they leave the epidermis (Yanagihara et al., 1998) lyze these possibilities.
and is required for DC mobilization to lymph nodes (Fo¨r- This study reveals an unexpected role for cysLTs as
ster et al., 1999). Responses to CCL19 were markedly regulators of DC trafficking, uncovers a link between
attenuated in MRP12/2 DCs or DCs treated briefly with cysLTs and chemotaxis to CCL19 that distinguishes this
the MRP1 antagonist MK571. A short incubation with chemokine from CCL21, and identifies a role for CCL19
cysLTs reversed this block. Since CCL19 and CCL21 in DC migration from the epidermis in vivo. New ques-
have so far been reported to share the chemotactic tions raised by these experiments include how signals
receptors CCR7 and a new receptor expressed in imma- induced by cysLTs converge with those emanating from
ture DCs (Gosling et al., 2000), it is surprising that the two chemokine receptor engagement, whether and when
chemokines showed distinct requirements for cysLTs. lymphatic endothelial cells express CCL19 in the periph-
ery, whether CCR7 is in fact the primary receptor thatConsistent with previous observations that epidermal
Cell
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photographic system (Figures 5C–5E) or an Olympus Provis AX70mediates both cysLT-dependent responses to CCL19
microscope equipped with a digital imaging system and Metamorphand the cysLT independence of CCL21, and whether
software for analysis (Figures 4, 5A, and 5B).other chemokines share with CCL19 a dependence on
cysLTs to induce optimal chemotactic responses. Flow Cytometry
For flow cytometric detection of intracellular epitopes recognized
Experimental Procedures by anti-MDR-1 and anti-MRP1 mAbs, cells were fixed in freshly
prepared, neutralized 1% paraformaldehyde for 5 min on ice. Cells
Materials were washed and incubated in PBS containing 0.5% NP-40 (Pierce)
MK571 was purchased from Biomol (Plymouth Meeting, PA). FITC for 1 min on ice. Cells were washed and then incubated in 2 mg/ml
(isomer 1) was obtained from Sigma (St. Louis, MO). Mouse anti- mouse anti-MDR-1 mAb C219, rat anti-MRP1 mAb MRPr1, rat 2A1
human MDR-1 mAb C219, which cross-reacts with an epitope in mAb, mouse IgG2a UPC10 (Sigma), or rat IgG2a R35–95 (Phar-
the cytoplasmic domain of mouse MDR1a/1b, was from Centocor Mingen) for 30 min on ice. After washing, bound mAbs were detected
(Philadelphia, PA). Rat anti-mouse MRP1 mAb MRPr1 cross-reacts with rabbit anti-mouse FITC (Dako Corp., Carpinteria, CA) or goat
with human MRP1 and was obtained from Signet Laboratories (Ded- anti-rat FITC (Jackson Immunoresearch). For studies to identify DCs
ham, MA). Purified goat IgG and specific neutralizing pAbs against in lymph node cell suspensions, nonpermeabilized cells were
CCL19 were purchased from R&D Systems (Minneapolis, MN). Anti- stained with PE-conjugated anti-CD11c or control anti-TNP mAb
CCL19 pAb does not cross-react with murine CCL21 or any of 16 (PharMingen).
other mouse chemokines tested.
FITC Sensitization and Migration Assays
Mice
Mice were anesthetized using methoxyfluorane and the dorsal skin
MRP1-deficient mice were generated as described previously (Lor-
was clipped. FITC (8 mg/ml) was dissolved in equal volumes of
ico et al., 1998). These mice and MRP11/1 controls were maintained
acetone and dibutyl phthalate (Sigma) and was applied in 25 ml
on a mixed background (129 3 C57/BL6). Typically, female mice at
aliquots with a pipet tip. FITC was applied to the ear skin or three
age 2–3 months were used for experiments, but similar results were
applications were made on each side of the mouse in areas of
obtained with male mice. Mdr1a/1b2/2 mice on an FVB/N back-
skin that drain to axillary, brachial, and inguinal lymph nodes. Cell
ground and MDR1a/1b1/1 FVB/N controls were purchased from Ta-
suspensions of total lymph node cells were prepared by incubating
conic Farms (Germantown, NY). 5-LO2/2 and matched controls were
the pooled axillary, brachial, and inguinal lymph nodes (left and right
from Jackson Laboratories (Bar Harbor, ME).
sides of each mouse were independently analyzed) at 378 C in 400
U/ml collagenase D (Boehringer Mannheim, Indianapolis, IN) for 30
Efflux of Synthetic Substrates by Multidrug Resistance Proteins
min, with addition of 10 mM EDTA for the last 5 min. Single cell
DCs that emigrated from ear explants or which were prepared from
suspensions were collected after gently pressing the digested tissue
bone marrow progenitors were incubated at 378C for 30 min in 4
through a 70 mm mesh strainer (Falcon cell strainers, Fisher). Total
mg/ml Fluo-3 (Molecular Probes, Eugene, OR) or 250 ng/ml FITC.
cells were enumerated for each sample, and the samples were
Cells were chilled to 48C, washed twice in cold PBS, and resus-
prepared for two-color flow cytometric analysis by staining with
pended in RPMI-1640 supplemented with 5% fetal bovine serum.
PE-conjugated anti-CD11c mAb (PharMingen). The number of
An aliquot was kept at 48C to document the extent of dye uptake.
FITC1CD11c1 DCs per lymph node sample was calculated after
Other cells were incubated at 378C for 60 min. Then cells were
counting the number of total lymph node cells and multiplying by
washed in cold PBS and immediately analyzed by flow cytometry
the percent of double-positive cells determined by FACS analysis.
using the FL1 channel.
Popliteal lymph nodes were used as a negative control, and their
analysis demonstrated that FITC1 cells were found only in lymph
Immunoblotting
nodes draining the areas of skin where FITC was applied. A time
Plasma membrane–enriched microsomes were prepared from 35 3
course revealed that maximal accumulation of FITC1CD11c1 DCs
106 human skin DCs or 15 3 106 mouse bone marrow–derived DCs.
cells was reached 18 hr after FITC application. All FITC1 cells ob-
Cells were lysed in hypotonic buffer (Kim et al., 1998) and by me-
served in lymph node suspensions were CD11c1.
chanical disruption in a Dounce homogenizer. After a low-speed
centrifugation to remove nuclei and unbroken cells, the supernatant
Latex-bearing DC Migration Assaywas centrifuged at 36,000 3 g for 13 min to remove mitochondria.
This assay was conducted as detailed previously (Randolph et al.,Microsomes were pelleted from the supernatant by a final centrifu-
1999a).gation at 100,000 3 g for 30 min. The pelleted membranes were
resuspended in 20 mM Tris-HCl buffer containing 1 mM dithiothreitol
Leukotrienes(pH 7.25). Protein assays were conducted (BCA assay, Pierce, Rock-
Leukotrienes A4 methyl ester, C4 and D4 were purchased from Bio-ford, IL), and 5 mg of microsomal proteins per lane were separated on
mol. Aliquots were prepared and partially dried under N2 gas. Ex-a 4%–12% gradient gel and tranferred to a nitrocellulose membrane.
treme care was taken at all times to minimize exposure to light andAfter blocking with 5% milk, the membrane was incubated overnight
oxygen. Aliquots were stored at 2808C and were used within 1with anti-MDR mAb C219 (3 mg/ml) or anti-MRP1 mAb MRPr1 (1:20
week. Dilutions were made in PBS (for intracutaneous injection)dilution of culture supernatant). These mAbs were detected with
or chemotaxis buffer. Intracutaneous injections were made with ahorseradish peroxidase-conjugated anti-mouse or anti-rat IgG, re-
tuberculin syringe (30 gauge needle, z25 ml each injection).spectively, and ECL substrates (Amersham, Arlington Heights, IL).
Skin Explant CulturesImmunostaining
Methods previously described for establishing and evaluating DCEpidermal sheets were prepared according to the previously de-
migration using human (Randolph et al., 1998) or mouse skin ex-scribed method of Lukas et al. (1996). Cryopreserved tissue sections
plants (Ortner et al., 1996) were followed.(5 mm) were fixed in acetone and incubated for 45 min in 1% normal
mouse serum containing 2 mg/ml PE-conjugated anti-B220, CD8,
Preparation of DCs from Bone Marrow CellsCD11c, I-Ab (MHC II), or hamster IgG (PharMingen, San Diego, CA);
Bone marrow–derived DCs were prepared essentially as describedbiotinylated anti-DEC-205; rat IgG2a control mAb R35–95 (Phar-
(Inaba et al., 1992b), except that subpopulations of bone marrowMingen); rat 2A1 mAb; rat SER-4 mAb; or rat anti-Cadherin 5 mAb
cells were not immunodepleted at initiation of culture (Lutz et al.,TEA 1 (Leach et al., 1993). The latter was detected by a second
1999). DCs were assayed for chemotaxis at day 7 or day 8.incubation in Cy3-conjugated streptavidin (Sigma) or Cy3-conju-
gated donkey anti-rat IgG (Jackson Immunoresearch Laboratories,
Inc., West Grove, PA). Sections were washed 3 times in PBS and Chemotaxis Assays
DCs were preincubated for 30 min or 1 hr with RPMI-1640 supple-mounted in Gel/Mount (Fisher, Pittsburgh, PA). Preparations were
examined using a Zeiss Axioplan 2 equipped with a conventional mented with 5% FBS containing 25 mM MK571, 100 nM LTD4, 200
Role of MRP1 in Dendritic Cell Migration
767
nM LTC4, or no additive. Cells were washed and resuspended in Gunn, M.D., Tangemann, K., Tam, C., Cyster, J.G., Rosen, S.D.,
and Williams, L.T. (1998). A chemokine expressed in lymphoid highchemotaxis buffer consisting of RPMI-1640 containing 20 mM
HEPES and 0.5% bovine serum albumin. Recombinant human endothelial venules promotes the adhesion and chemotaxis of naive
T lymphocytes. Proc. Natl. Acad. Sci. USA 95, 258–263.CCL19 and CXCL12 (gift from Dr. M. Baggiolini), and human CCL21
(gift from Dr. M. D. Gunn) were resuspended in the same medium Gunn, M.D., Kyuwa, S., Tam, C., Kakiuchi, T., Matsuzawa, A., Wil-
and added to the lower wells of a 48-well chemotaxis chamber liams, L.T., and Nakano, H. (1999). Mice lacking expression of sec-
(Neuro Probe; Cabin John, MD). Control wells received medium ondary lymphoid organ chemokine have defects in lymphocyte hom-
without chemoattractant. DCs added to the upper compartment of ing and dendritic cell localization. J. Exp. Med. 189, 451–460.
the chamber (5 3 104 cells/well) were separated from the lower
Inaba, K., Steinman, R.M., Witmer-Pack, M., Aya, H., Inaba, M.,compartment by a polycarbonate filter with 5 mm pores (Neuro
Sudo, T., Wolpe, S., and Schuler, G. (1992a). Identification of prolifer-Probe). The number of DCs that migrated to the lower surface of
ating dendritic cell precursors in mouse blood. J. Exp. Med. 175,the filter in a 2 hr incubation was counted in 5 high-power fields per
1157–1167.well.
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S.,
Muramatsu, S., and Steinman, R.M. (1992b). Generation of largeRT-PCR
numbers of dendritic cells from mouse bone marrow cultures sup-The primers and PCR conditions used to examine expression of
plemented with granulocyte/macrophage colony-stimulating factor.mRNA for CCR7 were as previously described (Yanagihara et al.,
J. Exp. Med. 176, 1693–1702.1998).
Ishikawa, T., Mu¨ller, M., Klu¨nemann, C., Schaub, T., and Keppler,
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